Accepted for Publication: September 27, 2014.
Published Online: December 22, 2014. doi:10.1001/jamainternmed.2014.6786.
Study concept and design: Mugwanya, Wyatt, Celum, Donnell, Tappero, Ronald, Baeten.
Acquisition, analysis, or interpretation of data: Mugwanya, Wyatt, Celum, Donnell, Mugo, Kiarie, Baeten.
Drafting of the manuscript: Mugwanya, Baeten.
Critical revision of the manuscript for important intellectual content: Mugwanya, Wyatt, Celum, Donnell, Mugo, Tappero, Kiarie, Ronald, Baeten.
Statistical analysis: Mugwanya, Donnell, Kiarie, Baeten.
Obtained funding: Wyatt, Celum, Baeten.
Administrative, technical, or material support: Mugwanya, Mugo, Tappero, Baeten.
Study supervision: Mugwanya, Wyatt, Celum, Mugo, Ronald, Baeten.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by grant OPP47674 from the Bill and Melinda Gates Foundation and grants R01MH095507 and R01DK100272 from the US National Institutes of Health; study medication was donated by Gilead Sciences.
Role of the Funder/Sponsor: The supporting institutions had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The Partners PrEP Study Team members, University of Washington Coordinating Center and Central Laboratories, Seattle,are Connie Celum (principal investigator, protocol cochair), Jared M. Baeten (medical director, protocol cochair), Deborah Donnell (protocol statistician), Robert W. Coombs, Lisa Frenkel, Craig W. Hendrix, Jairam R. Lingappa, M. Juliana McElrath. The 9 study sites and the Partners PrEP Study Team principal investigators at those sites are as follows: (1) Eldoret, Kenya (Moi University, Indiana University): Kenneth H. Fife, Edwin Were; (2) Kabwohe, Uganda (Kabwohe Clinical Research Center): Elioda Tumwesigye; (3) Jinja, Uganda (Makerere University, University of Washington): Patrick Ndase, Elly Katabira; (4) Kampala, Uganda (Makerere University): Elly Katabira, Allan Ronald; (5) Kisumu, Kenya (Kenya Medical Research Institute, University of California San Francisco): Elizabeth Bukusi, Craig R. Cohen; (6) Mbale, Uganda (The AIDS Support Organization, Centers for Disease Control and Prevention [CDC]–Uganda): Jonathan Wangisi, James D. Campbell, Jordan W. Tappero; (7) Nairobi, Kenya (University of Nairobi, University of Washington): James Kiarie, Carey Farquhar, Grace John-Stewart; (8) Thika, Kenya (University of Nairobi, University of Washington): Nelly R. Mugo; and (9) Tororo, Uganda (The AIDS Support Organization, CDC-Uganda): James D. Campbell, Jordan W. Tappero, Jonathan Wangisi.
Disclaimer: The views expressed are those of the authors and do not necessarily represent the views of the CDC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Additional Contributions: Data management was provided by DF/Net Research Inc, Seattle, Washington, and site laboratory oversight was provided by Contract Laboratory Services of the Wits Health Consortium, University of the Witwatersrand, Johannesburg, South Africa, who were both compensated for their contributions. We thank the HIV-1–serodiscordant couples who participated in this study for their invaluable contributions, and the teams at the study sites and at the University of Washington for work on data and sample collection and management.